Replies to post #339047 on Innovation Pharmaceuticals Inc (IPIX)

[Dall21]

Crunchbase says he works Nanoviricides as well as Innovation

[Rdunn88]

An amended patent from 2015 a nothing burger. Companies do this all the time that’s why Menon is listed and Leo’s old corporate address. Worth about zero to the stock price considering UP is grounded.

[loanranger]

"Why would a guy who doesn't work for the company patent our drug? Or is it a competing drug?"

I'll try to explain in the morning if you really want to know and it hasn't been sorted out by then.

[loanranger]

"Why would a guy who doesn't work for the company patent our drug?"
He isn't.

"Or is it a competing drug?"
It's not.

[CallMeCrazy]

Why I don't worry about IPIX's patents/licensing

PAUL GINSBURG, PHD
Scientific Advisor, Intellectual Property

Dr. Ginsburg is considered one of the foremost patent experts in the pharmaceutical and biotechnology fields. Dr. Ginsburg lectures widely on patent prosecution and licensing. Earlier in his career, he served as Head of the New York Patent Department at Pfizer Inc. Prior to his 20-year career at Pfizer, he was a senior attorney at Schering-Plough. Dr. Ginsburg was subsequently recruited by Merck and then by Fish & Neave. He is perhaps most well-known for authoring the patent covering Schering-Plough's blockbuster drug, Claritin. Since 2011, Dr. Ginsburg has advised Innovation, including authoring the patent for Kevetrin. He was elected to Phi Beta Kappa at the City College of New York. Dr. Ginsburg received a PhD (Chemistry) from the City University of New York and a JD from Columbia University.

http://www.ipharminc.com/scientific-advisors/

In reply to:

Does Leo know about this?

Why would a guy who doesn't work for the company patent our drug? Or is it a competing drug?

Go IPIX!